¼¼°èÀÇ ÀüÀÚ Ã³¹æÀü ½Ã½ºÅÛ ½ÃÀå
e-Prescription Systems
»óǰÄÚµå : 1514096
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 258 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,372,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,117,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ÀüÀÚ Ã³¹æÀü ½Ã½ºÅÛ ½ÃÀåÀº 2030³â±îÁö 52¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

2023³â¿¡ 17¾ï ´Þ·¯·Î Æò°¡µÈ ¼¼°èÀÇ ÀüÀÚ Ã³¹æÀü ½Ã½ºÅÛ ½ÃÀåÀº 2030³â¿¡´Â 52¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ 2023³âºÎÅÍ 2030³â±îÁö CAGRÀº 17.0%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÀüÀÚ Ã³¹æÀü ¼Ö·ç¼ÇÀº ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§±îÁö CAGR 16.3%¸¦ ±â·ÏÇÏ¿© 32¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀüÀÚ Ã³¹æÀü ¼­ºñ½º ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 18.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 4¾ï 6,600¸¸ ´Þ·¯, Áß±¹Àº CAGR 24.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀüÀÚ Ã³¹æÀü ½Ã½ºÅÛ ½ÃÀåÀº 2023³â 4¾ï 6,600¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 15¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç ºÐ¼® ±â°£ 2023³âºÎÅÍ 2030³â±îÁö CAGRÀº 24.9%·Î Àü¸ÁµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 12.3%¿Í 14.0%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 12.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀüÀÚ Ã³¹æÀü ½Ã½ºÅÛ-ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ

ÀüÀÚ Ã³¹æÀü ½Ã½ºÅÛÀº ó¹æÀüÀÇ µðÁöÅÐ »ý¼º, Àü¼Û ¹× ±âÀÔÀ» °¡´ÉÇÏ°Ô ÇÏ´Â °Ç°­ °ü¸® »ê¾÷ÀÇ Çõ½Å ±â¼úÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ó¹æÀü °úÁ¤À» °£¼ÒÈ­ÇÏ°í ±âÁ¸ Á¾ÀÌ Ã³¹æÀüÀ» ÀÇ·á Á¦°ø¾÷ü·ÎºÎÅÍ ¾à±¹À¸·Î Á÷Á¢ Àü¼ÛµÇ´Â µðÁöÅРó¹æÀüÀ¸·Î ´ëüÇÕ´Ï´Ù. ÀüÀÚ Ã³¹æÀü ½Ã½ºÅÛÀº Àб⠾î·Á¿î ÇÊ±â ¹× Àü±â ½Ç¼ö¿Í °°Àº Çʱâ ó¹æÀü°ú °ü·ÃµÈ ¿À·ùÀÇ À§ÇèÀ» ÁÙÀÓÀ¸·Î½á Á¤È®¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. ¶ÇÇÑ Ã³¹æÀüÀÇ Ã³¸® ½Ã°£À» ´ÜÃàÇϰí ȯÀÚÀÇ ´ë±â ½Ã°£À» ´ÜÃàÇÔÀ¸·Î½á È¿À²¼ºµµ Çâ»óµË´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ÀüÀÚ ÀÇ·á ±â·Ï(EHR)°ú ÅëÇÕÇÏ¿© ´õ ³ªÀº ¾à¹° °ü¸®¸¦ ÃËÁøÇϰí ÀÇ·á Á¦°ø¾÷ü°¡ ȯÀÚÀÇ Á¾ÇÕÀûÀÎ ¾à¹° ±â·Ï¿¡ ¾×¼¼½ºÇÏ°í ´õ ¸¹Àº Á¤º¸¸¦ ±â¹ÝÀ¸·Î ó¹æ °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ÀÌ ÅëÇÕÀº ÀáÀçÀûÀÎ ¾à¹° »óÈ£ ÀÛ¿ë, ¾Ë·¹¸£±â, Áߺ¹À» È®ÀÎÇÏ´Â µ¥ µµ¿òÀ̵Ǿî ȯÀÚÀÇ ¾ÈÀüÀ» Çâ»ó½Ãŵ´Ï´Ù.

ÀüÀÚ Ã³¹æ ½Ã½ºÅÛÀÇ ÃÖ±Ù ¹ßÀüÀº ±× ±â´É°ú äÅÃÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý Ç÷§Æû, ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼Ç, °í±Þ µ¥ÀÌÅÍ ºÐ¼® µîÀÇ ±â¼ú Çõ½ÅÀ» ÅëÇØ ÀüÀÚ Ã³¹æÀüÀº ´õ¿í »ç¿ëÇϱ⠽±°í »ç¿ëÀÚ Ä£È­ÀûÀ̾ú½À´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý ÀüÀÚ Ã³¹æ ½Ã½ºÅÛÀº È®À强°ú À¯¿¬¼ºÀ» Á¦°øÇϸç, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü´Â ¾îµð¼­³ª ó¹æ µ¥ÀÌÅÍ¿¡ ¾×¼¼½ºÇÒ ¼ö ÀÖ½À´Ï´Ù. ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼ÇÀº À̵¿ Áß¿¡ ó¹æÀ» °¡´ÉÇÏ°Ô Çϰí ÀÇ·á Á¦°ø¾÷ü¿Í ȯÀÚÀÇ ÆíÀǼºÀ» Çâ»ó½Ãŵ´Ï´Ù. °í±Þ µ¥ÀÌÅÍ ºÐ¼®À» ÅëÇØ ó¹æÀü ÆÐÅϰú µ¿ÇâÀ» ÆÄ¾ÇÇϰí ÀÇ·á±â°üÀÇ ¾÷¹« ÃÖÀûÈ­ ¹× ȯÀÚ °á°ú °³¼±À» Áö¿øÇÕ´Ï´Ù. ¶ÇÇÑ, ÀüÀÚ Ã³¹æ ½Ã½ºÅÛÀº ÀüÀÚ »çÀü ½ÂÀÎ(ePA)À» Áö¿øÇÏ°í º¸ÇèÀÚÀÇ ½ÂÀÎÀÌ ÇÊ¿äÇÑ ÀǾàǰÀÇ ½ÂÀÎ °úÁ¤À» °£¼ÒÈ­ÇÏ¿© Ä¡·á Áö¿¬À» ÁÙÀÔ´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ½Ã½ºÅÛ¿¡´Â ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×(ML)ÀÌ ÅëÇյǾî ÀÖ¾î ¿¹Ãø ´É·Â°ú ¸ÂÃãÇü ÀÇ·á Á¢±ÙÀÇ Ãß°¡ °­È­°¡ ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

ÀüÀÚ Ã³¹æÀü ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀº ¿©·¯ ¿äÀο¡ ÀÇÇØ ¾ß±âµË´Ï´Ù. ó¹æ ½Ç¼ö¸¦ ÁÙÀ̰í ȯÀÚÀÇ ¾ÈÀü¼ºÀ» ³ôÀ̱â À§ÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿Í ±ÔÁ¦ ¿ä°Ç Áõ°¡´Â Áß¿äÇÑ ÃËÁø¿äÀÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, °¢±¹¿¡¼­ÀÇ EHR µµÀÔÀÇ Àǹ«È­¿Í ÀÇ·á Á¤º¸ ±â¼úÀÇ ÃßÁøÀÌ ÀüÀÚ Ã³¹æÀü ½Ã½ºÅÛÀÇ µµÀÔÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¸¸¼º ÁúȯÀÇ È®»ê°ú ÀÌ¿¡ µû¸¥ ¾à¹° ó¹æ Áõ°¡´Â È¿À²ÀûÀΠó¹æ °ü¸® ¼Ö·ç¼ÇÀ» ÇÊ¿ä·Î ÇÏ°í ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ´Ù¾çÇÑ ÀÇ·á Ç÷§Æû °£ÀÇ ¿øÈ°ÇÑ µ¥ÀÌÅÍ ±³È¯À» ÃËÁøÇÏ´Â »óÈ£ ¿î¿ë °¡´ÉÇÑ ½Ã½ºÅÛ °³¹ß°ú °°Àº ±â¼ú ¹ßÀüµµ ½ÃÀå È®´ë¿¡ ±â¿©ÇÕ´Ï´Ù. °Ô´Ù°¡, ƯÈ÷ COVID-19 ÆÒµ¥¹ÍÀ» °è±â·Î ÇÑ ¿ø°Ý ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ¿ø°Ý Áø·áÀÇ ¿¬¼Ó¼ºÀ» È®º¸Çϴµ¥ À־ÀÇ ÀüÀÚ Ã³¹æÀü ½Ã½ºÅÛÀÇ Á߿伺À» ºÎ°¢Çϰí ÀÖ½À´Ï´Ù. ó¹æ ½Ç¼ö¸¦ ÃÖ¼ÒÈ­ÇÏ°í ¾÷¹« È¿À²¼ºÀ» Çâ»ó½ÃÄÑ °Ç°­ °ü¸® ºñ¿ëÀ» Àý°¨ÇÏ´Â µ¥ ÁßÁ¡À» µÎ°í ÀÖ´Â °Íµµ ÀüÀÚ Ã³¹æ ½Ã½ºÅÛÀÇ Ã¤¿ëÀ» ÃËÁøÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεé·ÎºÎÅÍ ÀüÀÚ Ã³¹æÀü ½Ã½ºÅÛ ½ÃÀåÀº °­·ÂÇÑ ¼ºÀå ±Ëµµ¸¦ ¹¦»çÇϰí ÀÖÀ¸¸ç, ÇコÄɾî Á¦°øÀÇ Çö´ëÈ­¿Í ȯÀÚ °á°úÀÇ °³¼±¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 14°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global e-Prescription Systems Market to Reach US$5.2 Billion by 2030

The global market for e-Prescription Systems estimated at US$1.7 Billion in the year 2023, is expected to reach US$5.2 Billion by 2030, growing at a CAGR of 17.0% over the analysis period 2023-2030. e-Prescription Solutions, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$3.2 Billion by the end of the analysis period. Growth in the e-Prescription Services segment is estimated at 18.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$466.0 Million While China is Forecast to Grow at 24.9% CAGR

The e-Prescription Systems market in the U.S. is estimated at US$466.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 24.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.3% and 14.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.9% CAGR.

e-Prescription Systems - Key Trends and Drivers

E-prescription systems, or electronic prescribing systems, represent a transformative technology in the healthcare industry, enabling the digital creation, transmission, and filling of prescriptions. These systems streamline the prescription process, replacing traditional paper prescriptions with digital ones that are transmitted directly from healthcare providers to pharmacies. E-prescription systems improve accuracy by reducing the risk of errors associated with handwritten prescriptions, such as illegible handwriting and transcription mistakes. They also enhance efficiency, allowing for faster prescription processing and reducing wait times for patients. Furthermore, these systems facilitate better medication management by integrating with electronic health records (EHRs), enabling providers to access comprehensive patient medication histories and make more informed prescribing decisions. This integration helps in identifying potential drug interactions, allergies, and duplications, thereby improving patient safety.

Recent advancements in e-prescription systems have expanded their capabilities and adoption. Innovations such as cloud-based platforms, mobile applications, and advanced data analytics have made e-prescribing more accessible and user-friendly. Cloud-based e-prescription systems offer scalability and flexibility, allowing healthcare providers to access prescription data from any location. Mobile applications enable on-the-go prescribing, enhancing convenience for both providers and patients. Advanced data analytics provide insights into prescribing patterns and trends, helping healthcare organizations optimize their practices and improve patient outcomes. Additionally, e-prescription systems now support electronic prior authorization (ePA), streamlining the approval process for medications that require insurer approval, thereby reducing delays in treatment. The integration of artificial intelligence (AI) and machine learning (ML) in these systems is also emerging, promising to further enhance their predictive capabilities and personalized medicine approaches.

The growth in the e-prescription systems market is driven by several factors. Increasing government initiatives and regulatory requirements aimed at reducing prescription errors and enhancing patient safety are significant drivers. For example, mandates for the adoption of EHRs and the promotion of health information technology in various countries have accelerated the implementation of e-prescription systems. The growing prevalence of chronic diseases and the corresponding rise in medication prescriptions necessitate efficient prescription management solutions, further propelling market growth. Technological advancements, such as the development of interoperable systems that facilitate seamless data exchange across different healthcare platforms, are also contributing to market expansion. Additionally, the increasing demand for telehealth services, especially in the wake of the COVID-19 pandemic, has highlighted the importance of e-prescription systems in ensuring continuity of care remotely. The enhanced focus on reducing healthcare costs by minimizing prescription errors and improving operational efficiencies is another critical factor driving the adoption of e-prescription systems. These factors collectively underscore the robust growth trajectory of the e-prescription systems market, reflecting its integral role in modernizing healthcare delivery and improving patient outcomes.

Select Competitors (Total 14 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â